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Background: Therapeutic angiogenesis with vascular endothelial growth factor (VEGF), delivered either via
recombinant protein infusion or via gene therapy, has shown promise in preclinical models of various diseases
including myocardial infarction, renovascular disease, preeclampsia, and neurodegenerative disorders. However,
dosing, duration of expression, and tissue specificity are challenges to VEGF gene therapy, and recombinant VEGF
delivery suffers from extremely rapid plasma clearance, necessitating continuous infusion and/or direct injection at
the site of interest.
Methods: Here we describe a novel growth factor purification and delivery system (PADS) generated by fusion of
VEGF121 to a protein polymer based on Elastin-like Polypeptide (ELP). ELP is a thermally responsive biopolymer
derived from a five amino acid repeat sequence found in human tropoelastin. VEGFPADS were constructed by fusion
of the ELP coding sequence in-frame with the VEGF121 coding sequence connected by a flexible di-glycine linker.
In vitro activity of VEGFPADS was determined using cell proliferation, tube formation, and migration assays with
vascular endothelial cells. Pharmacokinetics and biodistribution of VEGFPADS in vivo were compared to free VEGF in
mice using quantitative fluorescence techniques.
Results: ELP fusion allowed for recombinant expression and simple, non-chromatographic purification of the
ELP-VEGF121 chimera in yields as high as 90 mg/L of culture and at very high purity. ELP fusion had no effect on
the VEGF activity, as the VEGFPADS were equally potent as free VEGF121 in stimulating HUVEC proliferation, tube
formation, and migration. Additionally, the VEGFPADS had a molecular weight five-fold larger than free VEGF121,
which lead to slower plasma clearance and an altered biodistribution after systemic delivery in vivo.
Conclusion: PADS represent a new method of both purification and in vivo stabilization of recombinant growth
factors. The use of this system could permit recombinant growth factors to become viable options for therapeutic
angiogenesis in a number of disease models.
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Purification and delivery systemBackground
Loss of VEGF signaling or increase in anti-angiogenic
factors have been implicated in many diseases including
preeclampsia [1], renovascular disease [2], and neurode-
generative diseases [3,4]. Therapeutic angiogenesis with
supplemental VEGF administration has shown preclin-
ical efficacy in multiple animal models [4-10]. However,* Correspondence: gbidwell@umc.edu
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radation, exogenous VEGF must be continuously admin-
istered, often directly at the desired site of action, to
achieve therapeutic benefit. The goal of this study is to
characterize a biopolymer fusion with human VEGF. Fu-
sion with this biopolymer, a synthetic protein based on
human elastin, allows for recombinant production of
large amounts of the chimeric protein, very simple non-
chromatographic purification, and reduced plasma clear-
ance relative to free VEGF.
Supplemental VEGF has been supplied in several pre-
clinical disease models by either direct administration of. This is an Open Access article distributed under the terms of the Creative
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In a dog model of myocardial infarction, direct infusion
of VEGF at the infarcted site improved blood flow and
increased neovascular development [10]. However, daily
infusion for 28 days directly at the site of the infarcted
tissue was required. Similarly, continuous VEGF infusion
into the myocardium for six weeks decreased the size of
the ischemic zone and improved cardiac function in a
swine model of myocardial infarction [8]. In renovascu-
lar disease, microvascular rarefaction associated with
renal artery stenosis was associated with a marked re-
duction in bioavailable VEGF in the kidney [2], and
intrarenal administration of VEGF improved renal func-
tion, increased microvessel density, and improved renal
scarring in a swine model of renal artery stenosis [6]. In
preeclampsia, increased production of the VEGF antag-
onist sFlt-1 has been shown to be a major driver of the
maternal syndrome [11-14]. Direct administration of re-
combinant VEGF via continuous intraperitoneal infusion
sequestered the increased circulating sFlt-1 and reduced
the hypertension [5]. VEGF supplementation has also
shown efficacy in preclinical models of neurodegenera-
tive diseases. In spinocerebellar ataxia type I (SCA1),
VEGF mRNA and protein levels were decreased in the
Purkinje layer of SCA1 transgenic mice, and VEGF ad-
ministration improved the cerebellar pathology and the
motor function in these mice [4]. However, direct intra-
cerebroventricular administration was required. Similarly,
loss of hypoxia inducible VEGF in neural tissue in trans-
genic mice lead to degeneration of lower motor neurons,
causing a syndrome similar to amyotrophic lateral scler-
osis [3]. In vitro, VEGF protected motor neurons from
apoptosis induced by several stressors, and in vivo, VEGF
protected dorsal root ganglion neurons against paclitaxel
or hyperglycemia-induced neurotoxicity [7].
These results suggest value for supplemental VEGF
therapy in a myriad of disease models. However, they also
highlight several drawbacks to recombinant VEGF ther-
apy. VEGF has a very short plasma half-life. In humans, a
terminal half-life of 33.7 minutes was measured after a
20 minute infusion [15]. For this reason, continuous ad-
ministration, often directly at the target site, is required
for efficacy. To overcome this limitation, sustained release
methods have been developed. VEGF-loaded microspheres
were injected into hindlimb muscles in rats, and these
constructs resulted in slow release of VEGF over a period
of seven days and evidence of vascular remodeling at time
points as long as 70 days after a single injection [16]. In
another application, VEGF-loaded microspheres were in-
corporated into alginate hydrogels to generate an inject-
able, slow-release hybrid delivery system [17]. This
strategy lead to sustained release of VEGF over 28 days
and marked improvement in angiogenesis and limb-
sparing in a mouse model of hindlimb ischemia. In arecent report, a degradable VEGF-releasing hydrogel was
created by fusing VEGF to the coagulation factor fXIIIa
which was then crosslinked into fibrin hydrogels [18]. This
construct exhibited a controlled degradation and VEGF
release over a four week period, and yielded improved
angiogenesis, perfusion, and healing in hind limb ischemia
and in wound healing models.
In addition to its rapid clearance, recombinant VEGF
produced in bacteria or yeast must be purified by a labor-
intensive chromatographic protocol [19,20]. In a yeast
expression system, yields of 40 mg of VEGF121 per L of
culture have been reported using a nickel chromatography
purification protocol [20]. However, chromatographic
purification protocols are challenging to scale up to thera-
peutic production capacity, and the tooling required to do
so contributes to increasing the manufacturing cost of
goods (COGs).
Here we have developed a VEGF purification and deliv-
ery system (VEGFPADS) achieved by fusion of VEGF to a
thermally responsive biopolymer via a flexible diglycine
linker. Elastin-like polypeptide (ELP) is a genetically engi-
neered protein consisting of a five amino acid repeating
sequence [21]. This polypeptide has several unique prop-
erties that make it useful as a therapeutic delivery plat-
form. First, it is thermally responsive, existing as a soluble
protein below a characteristic transition temperature but
self-associating into aggregates above that transition
temperature [22]. This aggregation process is fully revers-
ible. Second, ELPs can be expressed in bacterial recombin-
ant expression systems, and they are easily purified due to
their thermally responsive properties [23,24]. After recom-
binant expression and cellular lysis, ELP can be specifically
separated from the soluble bacterial lysate by simply heat-
ing the solution or increasing the salt concentration in
order to trigger ELP aggregation. Repeated centrifugation
steps at temperatures above the ELP transition temperature
leads to isolation of very pure preparations of the polypep-
tide. Third, because they are genetically engineered, the
ELP sequence is easily modified to achieve the desired ELP
size and transition temperature [22], and therapeutic pro-
teins or peptides and targeting agents are easily fused to the
ELP gene to create chimeric therapeutics [24-29]. Finally,
because of its large size and its biocompatibility, ELP has
many properties desired in a drug delivery vector, including
a long plasma half-life [26,30], low immunogenicity [31,32],
and biodegradability.
Here we show, using a simple non-chromatographic
purification protocol, isolation of VEGFPADS as highly
purified protein in yields up to 90 mg/L of bacterial cul-
ture. The purification requires only a warm water bath
and a centrifuge and can be completed in 4 – 6 hours.
The VEGFPADS retained full VEGF activity as assessed
using endothelial cell proliferation, migration, and tube
formation assays. Also, VEGFPADS exhibited a slower
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unconjugated VEGF. We believe VEGFPADS, or growth
factor PADS in general, represent a new, simple way to
purify recombinant growth factors. They have the potential,
either as stand alone agents or in combination with the
novel controlled release methods recently described, to
function as stabilized agents for therapeutic angiogenesis.
Methods
Generation of constructs
The coding sequence for VEGF121 was synthesized with
codons optimized for expression in E. coli (Life Tech-
nologies), and inserted into a plasmid vector between
NdeI and BamHI restriction sites, with an SfiI site at the
N-terminus of the VEGF121 coding sequence. The entire
coding sequence was cloned into pET 25b + at the NdeI
and BamHI sites, and the ELP coding sequence was ex-
cised from pUC19-ELP and cloned into the SfiI site,
generating an in-frame fusion of ELP and VEGF121. The
ELP sequence contained 160 VPGxG repeats in which
the x residue was V, G, or A in a 1:7:8 ratio. All con-
structs were confirmed by DNA sequencing.
Purification of VEGFPADS
pET25b + vectors containing the VEGFPADS coding se-
quence were transformed into E. coli BLR(DE3), and
500 mL cultures were grown for 16 – 20 hours in 2L
flasks. The pET system produces low-level recombinant
protein expression even without induction [33]. Cells
were harvested by centrifugation, lysed by sonication,
and nucleic acids were precipitated with polyethylenei-
mine and removed by centrifugation. NaCl was added to
the soluble lysate to a concentration of 200 mg/mL, and
the solution was heated at 42°C until the VEGFPADS pre-
cipitated. The precipitated VEGFPADS were collected by
centrifugation, re-dissolved in cold PBS, centrifuged at
4°C to remove any un-dissolved precipitate, and this heat
cycling process was repeated 3 – 5 times until purified
protein was obtained. Purity was assessed by SDS-PAGE.
Cell culture
Human umbilical vein endothelial cells (HUVECs) were
obtained from ATCC and maintained in M200 medium
plus low serum growth supplement (Life Technologies) in
a humidified 37°C incubator at 5% CO2. All experiments
were performed on cells with <10 passages in culture.
Cells were removed from flasks by trypsinization and
counted using a Scepter® hand held cytometer (Millipore).
HUVEC proliferation assay
HUVECs were plated in 96 well plates (10,000 cells/well).
Cells were serum and growth factor starved for 24 h in
M200 medium without supplements then exposed to
the indicated concentration of VEGF121 (ProSpec) orVEGFPADS for 72 h. Cell number was determined using
the MTS aqueous cell proliferation assay (Promega).
Experiments were performed in quadruplicate, and
the data represent the mean ± s.e. of 3 independent
experiments.
HUVEC tube formation assay
Sterile, non-tissue culture treated 24 well plates were coated
with growth factor reduced Matrigel (BD Biosciences).
50,000 growth factor starved HUVECs were added per well
in M200 growth medium+ 0.1 mg/mL heparin without
serum growth supplements, and PBS vehicle control, ELP
control, VEGF121, or VEGFPADS were applied at a final con-
centration of 20 nM. Cells were incubated for 6 h at 37°C,
then cells were imaged with an inverted brightfield
microscope and 10× magnification objective. Five non-
overlapping fields were imaged per well, and the num-
ber of tubes per field were counted and averaged for
each well. Only tubes connecting two cell nodes were
counted. Data represent the mean ± s.e. of three inde-
pendent experiments.HUVEC migration assay
HUVECs (30,000 cells/well) were placed in the upper
well of Boyden chambers with 8 μm membrane pores
coated with Matrigel (Corning BioCoat™) in M200
medium + 1% fetal bovine serum + 0.1 mg/mL heparin.
The lower chamber contained identical medium plus
PBS vehicle control, ELP control, VEGF121, or VEGFPADS
at a final concentration of 10 nM or 50 nM. Cells were
incubated for 16 h at 37°C. The cells on the upper
surface of membranes were scratched off using cotton
Q-tips. Membranes were removed, stained with 0.1%
crystal violet in 10% ethanol, and the number of cells on
the lower membrane surface were counted in four inde-
pendent fields per membrane. Experiments were per-
formed in duplicate, and data represent the mean ± s.e.
of three independent experiments.Polypeptide labeling
VEGF121 (ProSpec) or VEGFPADS were dissolved at
100 μM in 0.1 M NaHCO3 buffer, pH 8.3, and Alexa Fluor
633® succininimidyl ester (Life Technologies) was added to
a final concentration of 300 μM. The reaction was allowed
to proceed for 1 h at room temperature, then unreacted
dye was removed by multiple washes with an Amicon
3,000 molecular weight cutoff spin filter (Millipore). Label-
ing efficiency was determined spectrophotometrically
using a method modified from [24]. Removal of unreacted
label was confirmed by TCA precipitation of the labeled
protein and assessing the free fluorophor levels in the
supernatant spectrophotometrically.
Figure 1 Purification and activity of VEGFPADS. a. SDS-PAGE gel
with silver staining demonstrating the purity of VEGFPADS and ELP
control polypeptides. Lane 1, ELP; Lane 2, VEGFPADS; Lane 3, VEGF121.
b. HUVEC cell proliferation was determined after 72h exposure to
ELP, VEGF, or VEGFPADS at the indicated concentrations using the
MTS cell proliferation assay. *Statistically significant increase versus
untreated cells (p = 0.0003, two-way ANOVA with post-hoc Bonferroni
multiple comparison).
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All animal use was approved by the Institutional Animal
Care and Use Committee at the University Of Mississippi
Medical Center and was carried out in accordance with
the National Institutes for Health Guide for the Care and
Use of Laboratory Animals. All procedures were carried
out under full surgical isoflurane anesthesia. C57Bl/6 mice
were catheterized in the femoral artery, and 123 nmol/kg
AlexaFluor 633 – labeled VEGF121 or VEGFPADS were
injected in the opposite femoral vein. Blood was sampled
intermittently for a period of four hours. Four hours after
injection, the animals were euthanized and the tissues re-
moved for ex vivo fluorescence analysis.
Plasma fluorescence was determined by direct meas-
urement of the fluorescence intensity of 2 μL plasma
samples with 610 nm excitation and 660 nm emission
using a fluorescence plate reader and a Nanoquant® plate
(Tecan). Standard curves of the injected proteins were
produced using known quantities of the injectate, and
standards were scanned using the same scan settings as
were used for plasma samples. Plasma fluorescence in-
tensity was fit to the standard curves to determine the
molar plasma concentration at each time point, and data
were averaged for all animals (n = 4 mice per group) and
represented as mean ± s.d. Averaged plasma clearance
data were fit to a two compartment pharmacokinetic
model as described previously [25].
Whole organ ex vivo fluorescence imaging was per-
formed using an IVIS Spectrum (Caliper Life Sciences,
Perkin Elmer) with 605 nm excitation, 660 nm emission,
and auto exposure. Mean fluorescence radiant efficiency
was determined for each organ using Living Image Soft-
ware (Caliper). 100 μL of each protein standard were
placed in wells of a black 96 well plate and imaged with
the same settings as were used for tissue imaging. Back-
ground autofluorescence from tissues of uninjected ani-
mals was subtracted from each organ’s fluorescence, and
mean fluorescence radiant efficiency of all organs were
fit to the standard curve values to determine tissue con-
centrations. Data were averaged for all animals (n = 4
mice per group) and represented as mean ± s.e.
Plasma stability and Dye release
Stability of VEGFPADS to proteolysis and stability of the
chemically linked fluorescent dye were determined by
in vitro incubation in mouse plasma. VEGFPADS were la-
beled with 5-(and-6)-carboxytetramethylrhodamine suc-
cinimidyl ester (Life Technologies) as described above.
Fluorescently labeled VEGFPADS were diluted 1:2 from a
200 μM stock in 100% mouse plasma and incubated up
to 24 h at 37°C. At the end of the incubation period,
samples were added to SDS-PAGE loading dye, heated
at 95°C for 5 minutes, and electrophoresed on a 4 – 20%
gradient gel under non-reducing conditions. Controlsamples of VEGFPADS in PBS and VEGFPADS in plasma
with no 37°C incubation (immediately mixed with PAGE
loading dye) were also run. The gel was imaged using an
IVIS Spectrum in fluorescence mode with 535 nm exci-
tation, 580 nm emission and a 1 minute exposure time.
To calculate protein degradation, total band intensity
(total fluorescent radiant efficiency) for the entire lane
and intensity of all bands < 50 kDa were measured. The
percentage of the total band intensity <50 kDa was de-
termined and expressed relative to the 0h incubation.
To detect dye release from the labeled proteins, an ali-
quot of the same protein/plasma mixture from each time
point were measured directly to detect the total fluores-
cence using a Nanoquant® plate and a fluorescence plate
reader with 543 nm excitation and 575 nm emission and
a gain value of 90. After measuring the total fluores-
cence, the protein component of each sample was pre-
cipitated by 1:1 mixture with 10% trichloroacetic acid
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The fluorescence of the supernatant, containing any
non-protein bound fluorophor, was measured using the
same settings. After correction for dilution, the percent-
age of non-protein bound fluorescence was calculated
and expressed as percent free dye.
Statistical analysis
Proliferation data were assessed using a two way ANOVA
for polypeptide agent and concentration factors, and a
Bonferroni multiple comparison was performed. Tube for-
mation and migration data were assessed using a one-way
ANOVA with a post hoc Bonferroni multiple comparison
to compare treatment groups. Differences in urine levels
were compared using a Student’s t-test. Organ biodistribu-
tion was assessed with a two way ANOVA for factors of
polypeptide treatment and organ type, and a Bonferroni
multiple comparison was used to assess significant differ-
ences. In all analyses, a p value of < 0.05 was considered
statistically significant.
Results and discussion
Purification and activity of VEGFPADS
The coding sequence for VEGF121 was cloned into a pET
expression vector in frame with the ELP coding sequence
to enable recombinant production. The chimeric ELP-
fused VEGF (VEGFPADS) was purified by taking advantage
of the thermally responsive property of the ELP moiety.
After bacterial lysis, the VEGFPADS were separated fromFigure 2 VEGFPADS stimulate tube formation in HUVECs. a. HUVEC tub
Matrigel and supplementing the media with 20 nM ELP, VEGF, or VEGFPADS
Data represent the mean ± se of four independent experiments. *p = 0.000other soluble proteins by increasing the salinity of the so-
lution and raising the temperature, which induces a revers-
ible aggregation of the ELP domain. Centrifugation under
these conditions selectively precipitated the VEGFPADS, and
they were re-solubilized by mixing in cold phosphate buff-
ered saline. As shown in Figure 1a, three thermal precipita-
tion cycles were sufficient to produce highly purified
VEGFPADS, and they migrated on a polyacrylamide gel at
approximately the expected molecular weight. This method
routinely yielded at least 90 mg of VEGFPADS per liter of
bacterial culture, and the entire purification protocol from
lysis to pure protein could be accomplished in less than
one day.
We next assessed whether the VEGFPADS maintained
their activity. It is possible that fusion of VEGF to the larger
ELP domain could affect its receptor binding and reduce or
eliminate its potency. To assess whether VEGFPADS could
stimulate proliferation of endothelial cells, HUVECs in cul-
ture medium in the absence of growth factors were exposed
to a concentration range of either free VEGF or VEGFPADS.
VEGFPADS were very potent stimulators of HUVEC prolif-
eration, achieving significant enhancement of proliferation
rate at a concentration of as low as 10 nM (Figure 1b). Im-
portantly, the potency of VEGFPADS was equivalent to that
of free recombinant VEGF121 in this proliferation assay.
We also tested the ability of VEGFPADS to stimulate
endothelial cell tube formation and migration. Tube
formation was assessed using a growth factor reduced
Matrigel assay. When plated on growth factor reducede formation was assessed 6 h after seeding on growth factor reduced
. b. Average tubes per field were counted for six fields per sample.
003, one-way ANOVA with post-hoc Bonferroni multiple comparison.
Figure 3 VEGFPADS stimulate HUVEC migration. a. HUVEC migration was assessed 16 h after seeding in the top chamber of Matrigel-coated
Boyden chambers in minimal media and supplementing the bottom chamber minimal media with ELP, VEGF, or VEGFPADS at the indicated
concentrations. b. Average cells per field were counted for four to seven fields per sample. Data represent the mean ± se of three independent
experiments. *p = 0.002, one-way ANOVA with post-hoc Bonferroni multiple comparison.
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(Figure 2a, left panel). However, when the medium was
supplemented with either free VEGF121 or VEGFPADS,
tube formation was stimulated (Figure 2a, right panels).
The ELP protein alone without VEGF fusion had no effect
on tube formation. Tubes were counted for each treat-
ment group, and this analysis revealed that VEGFPADS
were equally as potent as free VEGF121 at stimulating
HUVEC tube formation (Figure 2b). In addition to tube
formation, VEGFPADS also stimulated HUVEC migration.
As shown in Figure 3a, both free VEGF121 and VEGFPADS
stimulated HUVEC migration through Matrigel in a Boy-
den chamber invasion assay. Both proteins stimulated mi-
gration at concentrations as low as 10 nM and produced
equipotent and statistically significant migration at
100 nM (Figure 3b).
Pharmacokinetics and biodistribution of VEGFPADS versus
free VEGF
In addition to examining the VEGFPADS activity in vitro,
we also determined the pharmacokinetics (PK) and
biodistribution of VEGFPADS in comparison to free
VEGF121. Both free VEGF121 and VEGFPADS were fluo-
rescently labeled, and their PK and biodistribution were
determined in mice after bolus intravenous administra-
tion. Free VEGF121 had a very rapid plasma clearance
(Figure 4a), and fitting to a 2-compartment PK model
revealed a terminal plasma half-life of approximately
30 minutes (Table 1). This is consistent with other
reports of approximately a 30 minute half-life for recom-
binant VEGF in humans [15]. VEGFPADS cleared more
slowly than free VEGF121 (Figure 4a). Their plasma
clearance rate after IV infusion was about half the rate
of free VEGF121 (Figure 4b and Table 1), and as a result,
there was less fluorescence detectable in the urine at the
end of the experiment (Figure 4c). Four hours after the
infusion, the biodistribution was determined by ex vivo
whole organ fluorescence imaging. VEGF121 accumu-
lated most highly in the kidneys and the liver and had
very low levels in other organs. In contrast, VEGFPADS
accumulated more highly in the spleen and liver than
did free VEGF121, and the kidney deposition of VEGF-
PADS was significantly lower than for free VEGF121
(Figure 4d).
We also confirmed that the pharmacokinetic and biodis-
tribution results were not influenced by release of the dye
from the carrier or by significant VEGFPADS degradation.
Using SDS-PAGE analysis of VEGFPADS incubated in
plasma at 37°C in vitro for up to 24 h (Additional file 1:
Figure S1a), we determined that the protein undergoes a
slow degradation. By measuring the percentage of fluores-
cence present in bands less than 50 kDa, VEGFPADS
degraded at a rate of about 10% per day (Additional file 1:
Figure S1b). This value is consistent with our observationsof related ELP-based proteins in a rat model in vivo [34]
and with the rate observed for the parent ELP carrier in a
mouse model using a radiolabeling technique [35]. Also,
the rate of degradation is much slower than the plasma
clearance rate, indicating that protein degradation is not a
major factor on the time scale of the in vivo pharmacoki-
netic measurements. Protein biodegradation is likely the
mechanism by which VEGFPADS are eventually cleared
from deposits within tissues, but this process will occur
over a matter of days. Finally, by measuring the fluores-
cence of the protein/plasma mixture before and after TCA
precipitation, we observed that less than 2% of the fluoro-
phor was released from the protein over the course of a
24 h incubation in plasma (Additional file 1: Figure S1b).
In summary, by fusing VEGF to an engineered poly-
peptide carrier, we created a chimeric protein that is
very easily purified from a recombinant expression
system and maintains full VEGF activity as assessed in
human endothelial cells. The VEGFPADS system allows
for production of gram quantities of the recombinant
growth factor at very high purity with a very simple
purification scheme. This could represent a mechanism
to facilitate the production of growth factors in a fast
and inexpensive manner to make them more accessible
for research purposes or to produce them at the scale
needed for therapeutics. The system can easily be modi-
fied for the production of other growth factors, and we
are in the process of generating other VEGF isoforms as
ELP fusions as well as other GFPADS using several
growth factors of interest for various diseases. In
addition to maintaining their signaling ability, VEGFPADS
also showed extended plasma life and altered biodistri-
bution compared to the free growth factor. Given their
ease of production, their potency, and their increased
in vivo stability, VEGFPADS could prove to be useful thera-
peutics, either as standalone agents or in combination
with the controlled release strategies described above.
We are currently evaluating the therapeutic efficacy of
VEGFPADS in several disease models in which decreased
VEGF levels have been implicated. For example, in
preeclampsia, a major contributor to the maternal
hypertension and other symptoms is the VEGF antagon-
ist sFlt-1 [11]. We have recently described the ability of
the ELP carrier to prevent placental transfer and fetal
exposure of attached cargo [34], and we are evaluating
the ability of VEGFPADS to bind the excess sFlt-1 and
restore the available VEGF levels while preventing fetal
exposure to VEGF in a rodent preeclampsia model.
Also, VEGF has been demonstrated to increase micro-
vascular density and partially restore renal function in a
swine model of renovascular hypertension [6]. We are
currently evaluating the ability of VEGFPADS to increase
the VEGF bioavailability after systemic or direct intrarenal
administration and restore or preserve renal function.
Figure 4 VEGFPADS pharmacokinetics and biodistribution. a. Fluorescently labeled free VEGF or VEGFPADS were administered by IV injection to
C57/Bl6 mice. Plasma levels were determined by direct fluorescence quantitation and fit to a two-compartment pharmacokinetic model. b. VEGFPADS
had a slower plasma clearance rate than free VEGF, as was evidenced by lower levels in the urine at the end of the experiment c. Data represent the
mean ± sd of four mice per group. *p = 0.03, Student’s t-test. d. ELP fusion significantly altered the biodistribution of VEGF, increasing its levels in the
spleen and liver and reducing its levels in the kidney. *p <0.05, two-way ANOVA with post-hoc Bonferroni multiple comparison.
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Purkinje layer of the cerebellum in the neurodegenerative
disease SCA1 [4]. We are currently evaluating the brain
deposition, clearance kinetics, and therapeutic efficacy of
VEGFPADS versus unconjugated VEGF in a genetically
engineered mouse model of SCA1.Table 1 Pharmacokinetic parameters of VEGF121 and VEGFPAD
Central compartment volume of distribution Vc
Plasma clearance Cl
Area under curve AUC
Distribution half life t1/2 dist
Terminal half life t1/2 termConclusion
The work presented here establishes VEGFPADS as easily
produced, highly active modifications of recombinant
growth factors. The ELP system is easily amenable to modi-
fication with any desired proteinacious therapeutic, and
thus VEGFPADS are but one example of a therapeutic thatS
Free VEGF VEGFPADS
(L) 0.013 ± 0.005 0.013 ± 0.003
(L min-1) 0.0008 ± 0.0003 0.0004 ± 0.0004
(nmol min L-1) 3,863.8 ± 1,444.6 5,059.0 ± 528.5
(min) 8.6 7.2
(min) 30.2 52.4
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ease of purification and the in vivo stabilization conferred
by ELP fusion, we believe VEGFPADS have great potential
for therapeutic angiogenesis in a variety of disorders.
Additional file
Additional file 1: Figure S1. Protein Stability and Dye Release in
Plasma. a. The rate of degradation of VEGFPADS was determined after
incubation for various times in mouse plasma at 37°C by SDS-PAGE
analysis. b. The percentage of the total band intensity less than 50 kDa
was determined for each time point (left axis). Also, dye release was
detected by measuring the total plasma fluorescence before and after
TCA precipitation of the protein component (right axis).
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